Key Statistics
| Statistic | Value | Detail |
|---|---|---|
| Weight Loss | 28.7% | Phase 3, 68 weeks |
| Receptor Targets | 3 | GIP + GLP-1 + Glucagon |
| Weekly Injection | 1x | Subcutaneous |
| Liver Fat Reduced | 86% | Phase 2, 48 weeks |
| People Studied | 5.8k | Across all trials |
Mechanism of Action
Three Receptors, One Molecule
Unlike GLP-1 (which targets 1 receptor) or dual agonists (which target 2), Retatrutide activates three different hormone receptors at once. Each receptor triggers a different metabolic pathway — and together, they deliver more powerful effects than any single-target approach.
Biological Pathways
GIP Receptor (Strongest)
Glucose-dependent Insulinotropic Polypeptide
- Helps release insulin
- Improves fat metabolism
- Enhances satiety
GLP-1 Receptor (Moderate)
Glucagon-like Peptide-1
- Reduces appetite
- Slows digestion
- Improves blood sugar
Glucagon Receptor (Targeted)
The ‘Secret Weapon’
- Burns liver fat directly
- Increases energy burn
- Lowers cholesterol
Key Mechanism
The Third Receptor Advantage
The glucagon receptor is what sets Retatrutide apart. In trials, activating this receptor produced remarkable liver fat reduction (86%) and enhanced overall metabolic effects beyond what dual agonists achieve.
Source: Nature Cell Discovery
| Metric | Value |
|---|---|
| Weight Loss (12mg) | 28.7% |
| Weight Loss (9mg) | 26.4% |
| Liver Fat Reduction | -86% |
| Reached Normal Liver Fat | 93% |
Clinical Findings
| Metric | Value | Context |
|---|---|---|
| Average Weight Lost (highest dose) | 71 lbs | Phase 3 TRIUMPH-4, 68 weeks |
| Lost 5%+ at 12mg dose | 100% | All participants at highest dose |
| Lost 30%+ at 12mg dose | 39.4% | Previously only seen with bariatric surgery |
Phase 3 trial (TRIUMPH-4): 445 adults, 68 weeks, starting weight ~248 lbs. Results announced December 2025.
Preclinical Effects
| Effect | Model | Value |
|---|---|---|
| Phase 2 Weight Loss (12mg) | 48 weeks | -24.2% |
| Phase 2 Weight Loss (8mg) | 48 weeks | -22.8% |
| Prediabetes Reversed | Blood sugar normalization | 72% |
| Diabetic HbA1c Normalized | Type 2 diabetes | 82% |
Research Areas
Weight Management — Most weight loss observed in clinical trials
28.7% average weight loss at 12mg, with 39.4% of participants losing 30%+
Source: Eli Lilly Press Release (2025)
Liver Health — 86% liver fat reduction
93% of participants reached normal liver fat levels at 48 weeks
Source: Nature Medicine
Cardiovascular Health — Multiple heart health markers improved
Triglycerides ↓38%, LDL ↓18%, HDL ↑12%, BP ↓7mmHg
Source: Meta-Analysis (2024)
Joint Health — Knee osteoarthritis pain improvement
75.8% improvement in pain scores at 12mg; 12% became completely pain-free
Source: TRIUMPH trial data
Dosing Protocols
TRIUMPH Trial Protocol
Dose: 2mg → 4mg → 6mg → 9mg or 12mg (escalation) | Frequency: Once weekly subcutaneous | Duration: 68 weeks
- Gradual titration over 12 weeks
- Starting at 2mg reduces nausea
- Weekly subcutaneous injection
Phase 2 Protocol
Dose: 1mg, 4mg, 8mg, or 12mg weekly | Frequency: Once weekly | Duration: 48 weeks
- Dose-dependent weight loss
- 12mg produced -24.2% weight loss
- No tolerance observed
Pharmacokinetics
| Parameter | Value |
|---|---|
| Half-Life | ~6 days |
| Peak Concentration | 24-48 hours |
| Bioavailability | ~65% |
| Stability | Steady state at ~4 weeks |
| Excretion | Standard peptide metabolism |
| Metabolism | Subcutaneous injection, once weekly |
Safety Profile
| Issue | Incidence | Severity |
|---|---|---|
| Nausea | 43% | mild |
| Diarrhea | 33% | mild |
| Constipation | 25% | mild |
- Most GI side effects improve after first 4-8 weeks
- Side effects dose-dependent — lower doses had fewer
- No tolerance observed throughout 48-68 week studies
Compound Information
| Property | Value |
|---|---|
| Type | Synthetic peptide (triple agonist) |
| CAS Number | 2381089-83-2 |
| Molecular Weight | 4,731 g/mol |
| Amino Acids | 39 |
| Sequence | Modified with C20 diacid fatty acid chain |
| Formula | LY3437943 |
Frequently Asked Questions
Q: How is Retatrutide different from GLP-1 medications?
A: Retatrutide is a triple agonist targeting GIP, GLP-1, and Glucagon receptors. The addition of the glucagon receptor explains the enhanced weight loss (28.7% vs 17% for single agonists) and the remarkable 86% liver fat reduction.
Q: When will Retatrutide be FDA approved?
A: Phase 3 results are expected in 2026, with potential FDA approval around 2027. This timeline is subject to change based on regulatory processes.
Q: What about tolerance?
A: No tolerance was observed. Participants continued losing weight throughout 48-68 week studies without needing dose increases.
Q: What happens if you stop taking it?
A: Like other GLP-1 medications, weight regain is expected if treatment is discontinued. The TRIUMPH program is testing a 4mg maintenance dose for long-term use.
Q: What were the most common side effects?
A: GI side effects were most common: nausea (43%), diarrhea (33%), constipation (25%). Unique to Retatrutide is dysesthesia (tingling sensations) in ~21% at the highest dose, likely related to glucagon receptor activity.
References
- Jastreboff AM, et al. (2023) “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial” New England Journal of Medicine DOI: 10.1056/NEJMoa2301972
- Rosenstock J, et al. (2023) “Retatrutide for People with Type 2 Diabetes — A Phase 2 Trial” The Lancet
- Sanyal AJ, et al. (2024) “Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease” Nature Medicine
- Coskun T, et al. (2025) “Effects of Retatrutide on Body Composition” Lancet Diabetes & Endocrinology
- Eli Lilly Press Release (2025) “TRIUMPH-4 Phase 3 Trial Results” Eli Lilly